drugset / Trial / NCT03197740

A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease

NCT03197740

Phase 3 Completed 399 enrolled Icure Pharmaceutical Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of donepezil transdermal patch in patients with mild to moderate Alzheimer's disease. The primary objective is to demonstrate the non-inferiority of the test drug, IPI-301 (donepezil transdermal patch), to the comparator, Aricept tablet, after 24 weeks of treatment in patients with mild to moderate Alzheimer's disease in terms of improvement in cognitive function as assessed by the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) and in terms of global assessment as assessed by Clinician's Interview Based Impression of Change plus Caregiver Input (CIBIC-plus).

Timeline

Start
2017-10-12
Primary completion
2020-07-03
Completion
2020-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 5 mg Other
Subject Donepezil Small molecule 10 mg Other

Indications